BRIEF-Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410st

Reuters11-20 20:42

BRIEF-<a href="https://laohu8.com/S/OCGN">Ocugen</a> Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410st

Nov 20 (Reuters) - Ocugen Inc OCGN.O:

OCUGEN ANNOUNCES EUROPEAN MEDICINES AGENCY GRANTS ORPHAN MEDICINAL PRODUCT DESIGNATION FOR MODIFIER GENE THERAPY CANDIDATE OCU410ST FOR TREATMENT OF ABCA4-ASSOCIATED RETINOPATHIES INCLUDING STARGARDT DISEASE
OCUGEN INC - TO PURSUE ACCELERATED MARKETING AUTHORIZATION APPLICATION FOR OCU410ST

Source text: ID:nGNX6Zfsqg

Further company coverage: OCGN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484679118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484679118","market":"us","top_or_hot":-1,"title":"BRIEF-Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410st","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410st</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Ocugen Inc <span>OCGN.O</span>:</p><ul><li><p>OCUGEN ANNOUNCES EUROPEAN MEDICINES AGENCY GRANTS ORPHAN MEDICINAL PRODUCT DESIGNATION FOR MODIFIER GENE THERAPY CANDIDATE OCU410ST FOR TREATMENT OF ABCA4-ASSOCIATED RETINOPATHIES INCLUDING STARGARDT DISEASE</p></li><li><p>OCUGEN INC - TO PURSUE ACCELERATED MARKETING AUTHORIZATION APPLICATION FOR OCU410ST</p></li></ul><p>Source text: <span>ID:nGNX6Zfsqg</span></p><p>Further company coverage: <span>OCGN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410st</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410st\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8R9DFR:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410stNov 20 (Reuters) - Ocugen Inc OCGN.O:OCUGEN ANNOUNCES EUROPEAN ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8R9DFR:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8R9DFR:1","article_id":"2484679118","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484679118","pubTimestamp":1732106543,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410stNov 20 (Reuters) - Ocugen Inc OCGN.O:OCUGEN ANNOUNCES EUROPEAN ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4568":"美国抗疫概念","OCGN":"Ocugen","BK4139":"生物科技"},"translate_title":"简介-Ocugen宣布欧洲药品管理局授予修饰基因疗法候选药物Ocu410st孤儿药品称号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"BRIEF-Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410stNov 20 (Reuters) - Ocugen Inc OCGN.O:OCUGEN ANNOUNCES EUROPEAN MEDICINES AGENCY GRANTS ORPHAN MEDICINAL PRODUCT DESIGNATION FOR MODIFIER GENE THERAPY CANDIDATE OCU410ST FOR TREATMENT OF ABCA4-ASSOCIATED RETINOPATHIES INCLUDING STARGARDT DISEASEOCUGEN INC - TO PURSUE ACCELERATED MARKETING AUTHORIZATION APPLICATION FOR OCU410STSource text: ID:nGNX6ZfsqgFurther company coverage: OCGN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484679118"}